Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline Review, H1 2015

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline Review, H1 2015', provides an overview of the Relapsing Remitting Multiple Sclerosis (RRMS)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Relapsing Remitting Multiple Sclerosis (RRMS) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Relapsing Remitting Multiple Sclerosis (RRMS) Overview 10

Therapeutics Development 11

Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS)-Overview 11

Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS)-Comparative Analysis 12

Relapsing Remitting Multiple Sclerosis (RRMS)-Therapeutics under Development by Companies 13

Relapsing Remitting Multiple Sclerosis (RRMS)-Therapeutics under Investigation by Universities/Institutes 17

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Relapsing Remitting Multiple Sclerosis (RRMS)-Products under Development by Companies 21

Relapsing Remitting Multiple Sclerosis (RRMS)-Products under Investigation by Universities/Institutes 24

Relapsing Remitting Multiple Sclerosis (RRMS)-Companies Involved in Therapeutics Development 25

AbbVie Inc. 25

Actelion Ltd 26

Allozyne, Inc. 27

Amarna Therapeutics B.V. 28

Antisense Therapeutics Limited 29

Biogen, Inc. 30

Cognosci, Inc. 31

F. Hoffmann-La Roche Ltd. 32

Forward Pharma A/S 33

Genmab A/S 34

GlaxoSmithKline plc 35

Iltoo Pharma 36

Mapi Pharma Ltd. 37

MedImmune, LLC 38

Merck KGaA 39

Mitsubishi Tanabe Pharma Corporation 40

Neurotec Pharma SL 41

Novartis AG 42

Nuron Biotech, Inc. 43

Octapharma AG 44

Opexa Therapeutics, Inc. 45

RedHill Biopharma Ltd. 46

Sanofi 47

Synthetic Biologics, Inc. 48

Teva Pharmaceutical Industries Limited 49

XenoPort, Inc. 50

Zydus Cadila Healthcare Limited 51

Relapsing Remitting Multiple Sclerosis (RRMS)-Therapeutics Assessment 52

Assessment by Monotherapy Products 52

Assessment by Combination Products 53

Assessment by Target 54

Assessment by Mechanism of Action 57

Assessment by Route of Administration 60

Assessment by Molecule Type 62

Drug Profiles 64

(rifabutin + clarithromycin + clofazimine)-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

aldesleukin-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

ATL-1102-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

ATXMS-1467-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

AZ-17-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Cell Therapy for Relapsing Remitting Multiple Sclerosis-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

COG-133-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

daclizumab-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

diazoxide-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

dimethyl fumarate-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

estriol-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Gene Therapy for Relapsing and Remitting Multiple Sclerosis-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

glatiramer acetate ER-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

GSK-239512-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Guanabenz-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

HR-411-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

hydralazine-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

imilecleucel-t-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

immune globulin (human)-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

interferon beta-1b-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

interferon beta-1b-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

interferon beta-1b-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

laquinimod sodium-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

MEDI-551-Drug Profile 102

Product Description 102

Mechanism of Action 102

R&D Progress 102

MT-1303-Drug Profile 104

Product Description 104

Mechanism of Action 104

R&D Progress 104

ofatumumab-Drug Profile 105

Product Description 105

Mechanism of Action 105

R&D Progress 105

olesoxime-Drug Profile 110

Product Description 110

Mechanism of Action 110

R&D Progress 110

opicinumab-Drug Profile 113

Product Description 113

Mechanism of Action 113

R&D Progress 113

Pegylated Interferon-Beta-1b-Drug Profile 115

Product Description 115

Mechanism of Action 115

R&D Progress 115

ponesimod-Drug Profile 116

Product Description 116

Mechanism of Action 116

R&D Progress 116

siponimod-Drug Profile 118

Product Description 118

Mechanism of Action 118

R&D Progress 118

Small Molecule to Target CTLA4 and IFNGR for RRMS-Drug Profile 120

Product Description 120

Mechanism of Action 120

R&D Progress 120

vatelizumab-Drug Profile 121

Product Description 121

Mechanism of Action 121

R&D Progress 121

VAY-736-Drug Profile 122

Product Description 122

Mechanism of Action 122

R&D Progress 122

XP-23829-Drug Profile 124

Product Description 124

Mechanism of Action 124

R&D Progress 124

Relapsing Remitting Multiple Sclerosis (RRMS)-Recent Pipeline Updates 125

Relapsing Remitting Multiple Sclerosis (RRMS)-Dormant Projects 160

Relapsing Remitting Multiple Sclerosis (RRMS)-Discontinued Products 163

Relapsing Remitting Multiple Sclerosis (RRMS)-Product Development Milestones 165

Featured News & Press Releases 165

Feb 26, 2015: Abbvie's Ongoing Research In Neuroscience And Oncology On ZINBRYTA Will Be Featured At The 2015 American Academy Of Neurology Annual Meeting 165

Dec 17, 2014: First Patient Treated in Mapi Pharma's Phase IIa Clinical Trial of GA Depot for Relapsing Remitting Multiple Sclerosis 166

Nov 04, 2014: Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis 167

Sep 12, 2014: Detailed Results from Biogen Idec and AbbVie's Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA (Daclizumab High-Yield Process) 167

Sep 12, 2014: Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting 169

Jul 31, 2014: Expanded Data on Disability and Cognitive Improvements in Phase II Study of Synthetic Biologics' Trimesta in Multiple Sclerosis to be Presented at 2014 Joint ACTRIMS-ECTRIMS Meeting 170

May 30, 2014: Genmab Announces Ofatumumab Development Plans in RRMS and NMO 170

May 23, 2014: Teva and Active Biotech to Continue with the Development of Nerventra for Multiple Sclerosis Following Confirmation of CHMP Opinion 171

Apr 29, 2014: Synthetic Biologics Reports University of California, Los Angeles Announcement Of Preliminary Positive Topline Efficacy And Safety Results From Investigator-Led Phase 2 Study Of Trimesta For Relapsing-Remitting Multiple Sclerosis 172

Apr 07, 2014: ATL1102 for MS-US Patent Allowance Extends Strong IP Position 173

Appendix 174

Methodology 174

Coverage 174

Secondary Research 174

Primary Research 174

Expert Panel Validation 174

Contact Us 174

Disclaimer 175

List of Tables

Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS), H1 2015 11

Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS)-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 14

Number of Products under Development by Companies, H1 2015 (Contd..1) 15

Number of Products under Development by Companies, H1 2015 (Contd..2) 16

Number of Products under Investigation by Universities/Institutes, H1 2015 17

Comparative Analysis by Late Stage Development, H1 2015 18

Comparative Analysis by Clinical Stage Development, H1 2015 19

Comparative Analysis by Early Stage Development, H1 2015 20

Products under Development by Companies, H1 2015 21

Products under Development by Companies, H1 2015 (Contd..1) 22

Products under Development by Companies, H1 2015 (Contd..2) 23

Products under Investigation by Universities/Institutes, H1 2015 24

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by AbbVie Inc., H1 2015 25

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by Actelion Ltd, H1 2015 26

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by Allozyne, Inc., H1 2015 27

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by Amarna Therapeutics B.V., H1 2015 28

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by Antisense Therapeutics Limited, H1 2015 29

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by Biogen, Inc., H1 2015 30

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by Cognosci, Inc., H1 2015 31

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 32

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by Forward Pharma A/S, H1 2015 33

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by Genmab A/S, H1 2015 34

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by GlaxoSmithKline plc, H1 2015 35

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by Iltoo Pharma, H1 2015 36

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by Mapi Pharma Ltd., H1 2015 37

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by MedImmune, LLC, H1 2015 38

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by Merck KGaA, H1 2015 39

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 40

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by Neurotec Pharma SL, H1 2015 41

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by Novartis AG, H1 2015 42

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by Nuron Biotech, Inc., H1 2015 43

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by Octapharma AG, H1 2015 44

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by Opexa Therapeutics, Inc., H1 2015 45

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by RedHill Biopharma Ltd., H1 2015 46

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by Sanofi, H1 2015 47

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by Synthetic Biologics, Inc., H1 2015 48

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 49

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by XenoPort, Inc., H1 2015 50

Relapsing Remitting Multiple Sclerosis (RRMS)-Pipeline by Zydus Cadila Healthcare Limited, H1 2015 51

Assessment by Monotherapy Products, H1 2015 52

Assessment by Combination Products, H1 2015 53

Number of Products by Stage and Target, H1 2015 55

Number of Products by Stage and Mechanism of Action, H1 2015 58

Number of Products by Stage and Route of Administration, H1 2015 61

Number of Products by Stage and Molecule Type, H1 2015 63

Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics-Recent Pipeline Updates, H1 2015 125

Relapsing Remitting Multiple Sclerosis (RRMS)-Dormant Projects, H1 2015 160

Relapsing Remitting Multiple Sclerosis (RRMS)-Dormant Projects (Contd..1), H1 2015 161

Relapsing Remitting Multiple Sclerosis (RRMS)-Dormant Projects (Contd..2), H1 2015 162

Relapsing Remitting Multiple Sclerosis (RRMS)-Discontinued Products, H1 2015 163

Relapsing Remitting Multiple Sclerosis (RRMS)-Discontinued Products (Contd..1), H1 2015 164

List of Figures

Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS), H1 2015 11

Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS)-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 17

Comparative Analysis by Late Stage Development, H1 2015 18

Comparative Analysis by Clinical Stage Development, H1 2015 19

Assessment by Monotherapy Products, H1 2015 52

Number of Products by Top 10 Targets, H1 2015 54

Number of Products by Stage and Top 10 Targets, H1 2015 54

Number of Products by Top 10 Mechanism of Actions, H1 2015 57

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 57

Number of Products by Top 10 Routes of Administration, H1 2015 60

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 61

Number of Products by Top 10 Molecule Types, H1 2015 62

Number of Products by Stage and Top 10 Molecule Types, H1 2015 62

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Actelion Ltd

Allozyne, Inc.

Amarna Therapeutics B.V.

Antisense Therapeutics Limited

Biogen, Inc.

Cognosci, Inc.

F. Hoffmann-La Roche Ltd.

Forward Pharma A/S

Genmab A/S

GlaxoSmithKline plc

Iltoo Pharma

Mapi Pharma Ltd.

MedImmune, LLC

Merck KGaA

Mitsubishi Tanabe Pharma Corporation

Neurotec Pharma SL

Novartis AG

Nuron Biotech, Inc.

Octapharma AG

Opexa Therapeutics, Inc.

RedHill Biopharma Ltd.

Sanofi

Synthetic Biologics, Inc.

Teva Pharmaceutical Industries Limited

XenoPort, Inc.

Zydus Cadila Healthcare Limited

lapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics Asses

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutic Products under Development, Key Players in Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Relapsing Remitting Multiple Sclerosis (RRMS) Pipeline Overview, Relapsing Remitting Multiple Sclerosis (RRMS) Pipeline, Relapsing Remitting Multiple Sclerosis (RRMS) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com